Piper Sandler Raises Price Target on DexCom to $88
On June 15, 2026, Piper Sandler analyst Matt O’Brien raised its price target for DexCom (NASDAQ:DXCM) from $75 to $88 while maintaining an Overweight rating. The firm cited improved visibility into the company's long-term pipeline and growth potential following recent developments.
Tickers: $DXCM
Topics: Continuous Glucose Monitor (CGM) DexCom FDA Clearance Piper Sandler Stock Rating